Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07508488 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Deucravacitinib in the Treatment of Cicatricial Alopecias

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of May 11, 2026 to May 28, 2026v3
  3. Primary completion pushed from Sep 30, 2026 to Jun 30, 2028v2 Show 4 more changesShow less
    • Recruitment opened
    • Study completion pushed from Jan 21, 2027 to Sep 30, 2028
    • Start date: Apr 2026 to May 11, 2026
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Trial Details
NCT Number NCT07508488
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov